A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 307-313

  Shimamura, M ^a   Nagasawa, H ^b   Ashino, H ^a   Yamamoto, Y ^a   Hazato, T ^a   Uto, Y ^b   Hori, H ^b   Inayama, S ^c,d  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d Inst of Oriental Medical Sciences   (Japan)

Author keywords

Angiogenesis; Angiogenic factor; Endothelial cells; Hypoxia; Nitroimidazole

Indexed keywords

2 NITROIMIDAZOL 1 ACETYLHYDROXAMATE; 2 NITROIMIDAZOLE DERIVATIVE; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CYTOTOXIN; HYDROXAMIC ACID DERIVATIVE; KIN 841; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CATTLE; CELL FUNCTION; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOXIA; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; CARCINOMA, LEWIS LUNG; CATTLE; CELL DIVISION; CHICK EMBRYO; CHORION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMIDAZOLES; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITRO COMPOUNDS; PULMONARY ARTERY; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037468120     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600667     Document Type: Article

References (33)

1. Aboagye EO, Lewis AD, Johnson A, Workman P, Tracy M, Huxham IM (1995) The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Br J Cancer 72: 312-318
2. Adam MF, Gabalski EC, Bloch DA, Oehlert JW, Brown JM, Elsaid AA, Pinto HA, Terris DJ (1999) Tissue oxygen distribution in head and neck cancer patients. Head Neck 21: 146-153
3. Adams GE, Clarke ED, Flockhart IR, Jacobs RS, Sehmi DS, Stratford IJ, Wardman P, Watts ME, Parrick J, Wallace RG, Smithen CE (1979) Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med 35: 133-150
4. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumours by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032-4039
5. Brekken RA, Thorpe PE (2001) Vascular endothelial growth factor and vascular targeting of solid tumours. Anticancer Res 21: 4221-4229
6. Brown JM (1975) Selective radiosensitization of the hypoxic cells of mouse tumours with the nitroimidazoles metronidazole and Ro 7-0582. Radiat Res 64: 633-647
7. Brown JM, Yu NY, Brown DM, Lee WW (1981) SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 7: 695-703.
8. Bump EA, Taylor YC, Brown JM (1983) Role of glutathione in the hypoxic cell cytotoxicity of misonidazole. Cancer Res 43: 997-1002
9. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander Er, Black PM, Coleman CN (1998) Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 40: 65-70
10. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267: 10931-10934
11. Gleadle JM Ebert BL Firth JD, Ratcliffe PJ (1995) Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 268: C1362-C1368
12. Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J, Keys H, Asbell SO, Phillips TL (1999) Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 44: 513-517
13. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, Klein CE (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59: 1578-1583
14. Hori H, Murayama C, Mori T, Shibamoto Y, Abe M, Onoyama Y, Inayama S (1989) KIH-802: 2-nitroimidazole-1-acetohydroxamate as a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 16: 1029-1032
15. Iizuka M, Yamauchi M, Ando K, Hori N, Furusawa Y, Itsukaichi H, Fukutsu K, Moriya H (1994) Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia. Biochem Biophys Res Commun 205: 1474-1480
16. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y (2001) Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61: 6248-6254
17. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph SJ, Firie M, Torcia G, Cozzolino F, Kamada T, Stern D (1995) Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 92: 4606-4610
18. Lee K, Erturk E, Mayer R, Cockett AT (1987) Efficacy of antitumour chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate. Cancer Res 47: 5021-5024
19. Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40: 35-39
20. Moulder JE, Rockwell S (1984) Hypoxic fractions of solid tumours: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10: 695-712
21. Nagasawa H, Bando M, Hori H, Satoh T, Tada T, Onoyama Y, Inayama S (1992) Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers. Int J Radiat Oncol Biol Phys 22: 561-564
22. Oikawa T, Shimamura M (1996) Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 318: 93-96
23. Papadopoulou MV, Ji M, Rao, MK, Bloomer WD (1996) 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b] quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 8: 425-434
24. Potgens AJ, Lubsen NH, van Altena MC, Schoenmakers JG, Ruiter DJ, de Waal RM (1995) Vascular permeability factor expression influences tumour angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146: 197-209
25. Sheldon PW, Foster JL, Fowler JF (1974) Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug. Br J Cancer 30: 560-565
26. Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S (2001) Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun 289: 220-224
27. Shimo T, Kubota S, Kondo S, Nakanishi T, Sasaki A, Mese H, Matsumura T, Takigawa M (2001) Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett 174: 57-64
28. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
29. Stratford IJ, Stephens MA (1989) The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 16: 973-976
30. 2 at the cellular level. Br J Cancer 54: 453-457
31. Varghese AJ, Whitmore GF (1980) Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole. Cancer Res 40: 2165-2169
32. Walton MI, Workman P (1987) Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 36: 887-896
33. Yamaji T, Tsuboi H, Murata N, Uchida M, Kohno T, Sugino E, Hibino S, Shimamura M, Oikawa T (1999) Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate. Cancer Lett 145: 107-114